The injectable drug and drug delivery systems maker's Q4 EPS of 55 cents and sales of $1.1 bil both were up 8% vs. a year earlier and topped forecasts. But Hospira (HSP) issued '13 guidance of 1%-3% sales growth and 3%-9% EPS growth — below Wall St. projections. Hospira also said it received a new FDA notice about ongoing issues with medical-device quality at its Lake Forest, Ill., site. Shares, which hit a 6-month high early, dived 6.6%.
- Pharmaceuticals & Drug Trials
- drug delivery systems